130 related articles for article (PubMed ID: 35667517)
1. Introduction of mutant TP53 related genes in metabolic pathways and evaluation their correlation with immune cells, drug resistance and sensitivity.
Motlagh AV; Mahdevar M; Mirzaei S; Entezari M; Hashemi M; Hushmandi K; Peymani M
Life Sci; 2022 Aug; 303():120650. PubMed ID: 35667517
[TBL] [Abstract][Full Text] [Related]
2. TP53 mutations, expression and interaction networks in human cancers.
Wang X; Sun Q
Oncotarget; 2017 Jan; 8(1):624-643. PubMed ID: 27880943
[TBL] [Abstract][Full Text] [Related]
3. Immunometabolism characteristics and a potential prognostic risk model associated with TP53 mutations in breast cancer.
Jiang M; Wu X; Bao S; Wang X; Qu F; Liu Q; Huang X; Li W; Tang J; Yin Y
Front Immunol; 2022; 13():946468. PubMed ID: 35935965
[No Abstract] [Full Text] [Related]
4. Integrated Analysis of TP53 Gene and Pathway Alterations in The Cancer Genome Atlas.
Donehower LA; Soussi T; Korkut A; Liu Y; Schultz A; Cardenas M; Li X; Babur O; Hsu TK; Lichtarge O; Weinstein JN; Akbani R; Wheeler DA
Cell Rep; 2019 Jul; 28(5):1370-1384.e5. PubMed ID: 31365877
[TBL] [Abstract][Full Text] [Related]
5. Identification of critical pathways and hub genes in
Sun J; Zhang K; Cai Z; Li K; Zhao C; Fan C; Wang J
Biomark Med; 2019 Jul; 13(10):831-840. PubMed ID: 31116024
[No Abstract] [Full Text] [Related]
6. Differences in genetics and microenvironment of lung adenocarcinoma patients with or without TP53 mutation.
Zeng D; Hu Z; Yi Y; Valeria B; Shan G; Chen Z; Zhan C; Lin M; Lin Z; Wang Q
BMC Pulm Med; 2021 Oct; 21(1):316. PubMed ID: 34635074
[TBL] [Abstract][Full Text] [Related]
7. Effects of TP53 mutational status on gene expression patterns across 10 human cancer types.
Parikh N; Hilsenbeck S; Creighton CJ; Dayaram T; Shuck R; Shinbrot E; Xi L; Gibbs RA; Wheeler DA; Donehower LA
J Pathol; 2014 Apr; 232(5):522-33. PubMed ID: 24374933
[TBL] [Abstract][Full Text] [Related]
8. A TP53-Associated Immune Prognostic Signature for the Prediction of Overall Survival and Therapeutic Responses in Muscle-Invasive Bladder Cancer.
Wu X; Lv D; Cai C; Zhao Z; Wang M; Chen W; Liu Y
Front Immunol; 2020; 11():590618. PubMed ID: 33391264
[TBL] [Abstract][Full Text] [Related]
9. Significance of
Hou Y; Tan S; Wang G
Genet Test Mol Biomarkers; 2021 May; 25(5):346-354. PubMed ID: 33956533
[No Abstract] [Full Text] [Related]
10. Competition between p53 and YY1 determines PHGDH expression and malignancy in bladder cancer.
Shi T; Yuan Z; He Y; Zhang D; Chen S; Wang X; Yao L; Shao J; Wang X
Cell Oncol (Dordr); 2023 Oct; 46(5):1457-1472. PubMed ID: 37326803
[TBL] [Abstract][Full Text] [Related]
11. A TP53-associated immune prognostic signature for the prediction of the overall survival and therapeutic responses in pancreatic cancer.
Liu Y; Cheng L; Song X; Li C; Zhang J; Wang L
Math Biosci Eng; 2022 Jan; 19(1):191-208. PubMed ID: 34902987
[TBL] [Abstract][Full Text] [Related]
12. Alterations in TP53 Are a Potential Biomarker of Bladder Cancer Patients Who Benefit From Immune Checkpoint Inhibition.
Lyu Q; Lin A; Cao M; Xu A; Luo P; Zhang J
Cancer Control; 2020; 27(1):1073274820976665. PubMed ID: 33356494
[TBL] [Abstract][Full Text] [Related]
13. Significance of TP53 mutation in bladder cancer disease progression and drug selection.
Wu G; Wang F; Li K; Li S; Zhao C; Fan C; Wang J
PeerJ; 2019; 7():e8261. PubMed ID: 31871844
[TBL] [Abstract][Full Text] [Related]
14. [Expression and clinical significance of SETD2 in maligant pleural mesothelioma].
Yu M; Yu M; Zhu LJ; Yuan XY; Zhang X
Zhonghua Lao Dong Wei Sheng Zhi Ye Bing Za Zhi; 2021 Feb; 39(2):91-98. PubMed ID: 33691361
[No Abstract] [Full Text] [Related]
15. [TP53 mutations and molecular epidemiology].
Otsuka K; Ishioka C
Gan To Kagaku Ryoho; 2007 May; 34(5):683-9. PubMed ID: 17496437
[TBL] [Abstract][Full Text] [Related]
16. TP53 mutations as potential prognostic markers for specific cancers: analysis of data from The Cancer Genome Atlas and the International Agency for Research on Cancer TP53 Database.
Li VD; Li KH; Li JT
J Cancer Res Clin Oncol; 2019 Mar; 145(3):625-636. PubMed ID: 30542790
[TBL] [Abstract][Full Text] [Related]
17. Establishment and validation of an immune-based prognostic score model in glioblastoma.
Qin Z; Zhang X; Chen Z; Liu N
Int Immunopharmacol; 2020 Aug; 85():106636. PubMed ID: 32534425
[TBL] [Abstract][Full Text] [Related]
18. TP53 mutation hits energy metabolism and increases glycolysis in breast cancer.
Harami-Papp H; Pongor LS; Munkácsy G; Horváth G; Nagy ÁM; Ambrus A; Hauser P; Szabó A; Tretter L; Győrffy B
Oncotarget; 2016 Oct; 7(41):67183-67195. PubMed ID: 27582538
[TBL] [Abstract][Full Text] [Related]
19. Cancer type-dependent correlations between TP53 mutations and antitumor immunity.
Li L; Li M; Wang X
DNA Repair (Amst); 2020 Apr; 88():102785. PubMed ID: 32007736
[TBL] [Abstract][Full Text] [Related]
20. Association of Tumor Protein p53 and Ataxia-Telangiectasia Mutated Comutation With Response to Immune Checkpoint Inhibitors and Mortality in Patients With Non-Small Cell Lung Cancer.
Chen Y; Chen G; Li J; Huang YY; Li Y; Lin J; Chen LZ; Lu JP; Wang YQ; Wang CX; Pan LK; Xia XF; Yi X; Chen CB; Zheng XW; Guo ZQ; Pan JJ
JAMA Netw Open; 2019 Sep; 2(9):e1911895. PubMed ID: 31539077
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
